Glucokinase activator compositions for the treatment of diabetes

Patent metadata

Field	Value
Publication number	US-10004782-B2
Application number	US-201314071976-A
Country	US
Kind code	B2
Filing date	Nov 5, 2013
Priority date	May 17, 2012
Publication date	Jun 26, 2018
Grant date	Jun 26, 2018

Abstract

The present invention relates to pharmaceutical compositions comprising {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid (FRI-1) in combination with an anti-diabetic drug selected from the group consisting of metformin, sitagliptin or exenatide. The present invention also relates to the use of the pharmaceutical compositions in restoring insulin sensitivity and treating type II diabetes, including reducing body weight in subjects undergoing type II diabetes treatment.

First claim

What is claimed is:

1. A pharmaceutical composition comprising: i) {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid or a pharmaceutically acceptable salt thereof, ii) a GLP-1 analog or a pharmaceutically acceptable salt thereof; and iii) at least one pharmaceutically acceptable carrier, excipient, diluent or mixture thereof.

2. The composition of claim 1 , wherein the GLP-1 analog is exenatide, or a pharmaceutically acceptable salt thereof.

3. A method of treating type II diabetes comprising administering to a subject a glucokinase activator that is {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid or a pharmaceutically acceptable salt thereof and administering to the subject a GLP-1 analog or a pharmaceutically acceptable salt thereof, wherein insulin sensitivity in the subject is increased.

4. The method of claim 3 , wherein the subject is a human.

5. The method of claim 3 , wherein the glucokinase activator and the GLP-1 analog are administered in discrete dosage forms.

6. The method of claim 3 , wherein the glucokinase activator and the GLP-1 analog are administered in a single dosage form.

7. The method of claim 3 , wherein the GLP-1 analog is administered by injection and the glucokinase activator is administered orally.

8. The method of claim 3 , wherein the GLP-1 analog is exenatide or a pharmaceutically acceptable salt thereof.

9. A method of improving glycemic control by increasing a subject's insulin sensitivity comprising administering to a subject a glucokinase activator that is {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid or a pharmaceutically acceptable salt thereof and administering to the subject a GLP-1 analog or a pharmaceutically acceptable salt thereof.

10. The method of claim 9 , wherein the subject is a human.

11. The method of claim 9 , wherein the glucokinase activator and the GLP-1 analog are administered in discrete dosage forms.

12. The method of claim 9 , wherein the glucokinase activator and the GLP-1 analog are administered in a single dosage form.

13. The method of claim 9 , wherein the GLP-1 analog is administered by injection and the glucokinase activator is administered orally.

14. The method of claim 9 , wherein the GLP-1 analog is exenatide or a pharmaceutically acceptable salt thereof.

15. A method of treating a condition in a subject by increasing the subject's insulin sensitivity comprising administering to a subject {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid or a pharmaceutically acceptable salt thereof and administering a GLP-1 analog or a pharmaceutically acceptable salt thereof, wherein the condition is selected from the group consisting of a metabolic disorder, glucose intolerance, prediabetic state, insulin resistance, hyperglycemia, impaired glucose tolerance (IGT), Syndrome X, impaired fasting glucose (IFG), dyslipidemia, hyperlipidemia, hyperlipoproteinemia, hypertension, osteoporosis, non-alcoholic fatty liver disease (NAFLD), complications resulting from or associated with diabetes, cardiovascular disease, and obesity.

16. The method of claim 15 , wherein i) the complication resulting from or associated with diabetes is selected from the group consisting of nephropathy, retinopathy, neuropathy and impaired wound healing or ii) the cardiovascular disease is selected from the group consisting of arteriosclerosis and atherosclerosis.

17. A method of improving insulin sensitivity in a subject comprising administering to the subject {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid or a pharmaceutically acceptable salt thereof and administering to the subject a GLP-1 analog or a pharmaceutically acceptable salt thereof.

18. The method of claim 15 , wherein the subject is a human.

19. The method of claim 17 , wherein the subject is a human.

Assignees

• Vtv Therapeutics Llc

Inventors

• Valcarce Lopez Maria Carmen
• Fong Tung

Classifications

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61P3/08

  for glucose homeostasis (pancreatic hormones A61P5/48) · CPC title

• A61P9/12

  Antihypertensives · CPC title

• A61P3/06

  Antihyperlipidemics · CPC title